The estimated Net Worth of Sandra Boenisch is at least $1.2 Milion dollars as of 29 June 2021. Ms. Boenisch owns over 166,696 units of Anavex Life Sciences stock worth over $972,951 and over the last 8 years she sold AVXL stock worth over $0. In addition, she makes $224,560 as Principal Financial Officer a Treasurer at Anavex Life Sciences.
Sign up
Ms. Boenisch AVXL stock SEC Form 4 insiders trading
Sandra has made over 1 trades of the Anavex Life Sciences stock since 2021, according to the Form 4 filled with the SEC. Most recently she exercised 166,696 units of AVXL stock worth $698,456 on 29 June 2021.
The largest trade she's ever made was exercising 166,696 units of Anavex Life Sciences stock on 29 June 2021 worth over $698,456. On average, Sandra trades about 15,154 units every 0 days since 2016. As of 29 June 2021 she still owns at least 189,659 units of Anavex Life Sciences stock.
You can see the complete history of Ms. Boenisch stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sandra Boenisch biography
Sandra Boenisch serves as Principal Financial Officer, Treasurer of the Company. Ms. Boenisch is a Chartered Professional Accountant (CPA, CGA) with 14 years of accounting, audit, and financial reporting experience in a variety of industries, both in the United States and Canada. Ms. Boenisch has been an independent consultant, providing financial reporting services to a range of public companies in the United States and Canada since January 2012. From 2008 until 2012, Ms. Boenisch was employed at BDO Canada LLP (Vancouver, BC) where she was hired as a Senior Accountant and was later promoted to Manager, Audit Assurance. Ms. Boenisch specialized in managing assurance engagements for public companies in the United States and Canada. Prior to that, Ms. Boenisch worked for another public accounting firm from 2001 to 2008. As an independent consultant, Ms. Boenisch has acquired considerable experience in finance, governance, and regulatory compliance. She holds a BComm from Laurentian University.
What is the salary of Sandra Boenisch?
As the Principal Financial Officer a Treasurer of Anavex Life Sciences, the total compensation of Sandra Boenisch at Anavex Life Sciences is $224,560. There are 2 executives at Anavex Life Sciences getting paid more, with Christopher Missling having the highest compensation of $3,380,040.
How old is Sandra Boenisch?
Sandra Boenisch is 38, she's been the Principal Financial Officer a Treasurer of Anavex Life Sciences since 2015. There are 9 older and no younger executives at Anavex Life Sciences. The oldest executive at Anavex Life Sciences Corporation is Stephan Toutain, 55, who is the Chief Operating Officer.
What's Sandra Boenisch's mailing address?
Sandra's mailing address filed with the SEC is 650 FIFTH AVENUE,, 20TH FLOOR, NEW YORK, NY, 10111.
Insiders trading at Anavex Life Sciences
Over the last 18 years, insiders at Anavex Life Sciences have traded over $5,238,591 worth of Anavex Life Sciences stock and bought 135,460 units worth $453,776 . The most active insiders traders include Athanasios Skarpelos, Christopher U Missling a Elliot Favus. On average, Anavex Life Sciences executives and independent directors trade stock every 99 days with the average trade being worth of $335,876. The most recent stock trade was executed by Peter D.O. Donhauser on 14 June 2024, trading 2,835 units of AVXL stock currently worth $10,319.
What does Anavex Life Sciences do?
anavex life sciences corp. is a clinical stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodevelopmental and neurodegenerative diseases. anavex is currently in a phase 2a trial for alzheimer's disease (ad) with lead therapeutic, anavex 2-73, an orally available small molecule targeting protein misfolding and cellular stress through activating the sigma-1 receptor. part a topline data of our ongoing phase 2a trial demonstrate a favorable safety, bioavailability, dose-response curve and tolerability/risk profile. anavex 2-73 is a potential platform drug showing encouraging preclinical data rare neurodevelopmental disease: rett syndrome, as well is in epilepsy and multiple sclerosis (ms). in 2015, the company was awarded a research by the michael j. fox foundation (mjff) to study anavex 2-73 for the treatment of parkinson’s disease. headquartered in new york, anavex is an american publicly traded corporation quoted as avxl.
What does Anavex Life Sciences's logo look like?
Complete history of Ms. Boenisch stock trades at Anavex Life Sciences
Anavex Life Sciences executives and stock owners
Anavex Life Sciences executives and other stock owners filed with the SEC include:
-
Christopher Missling,
President, Chief Executive Officer, Secretary, Director -
Dr. Christopher U. Missling,
Chairman, Pres, CEO & Sec. -
Sandra Boenisch,
Principal Financial Officer, Treasurer -
Sandra Boenisch CPA, CPA, CGA,
Principal Financial Officer & Treasurer -
Claus van der Velden,
Independent Director -
Steffen Thomas,
Independent Director -
Athanasios Skarpelos,
Independent Director -
Elliot Favus,
Independent Director -
Peter Donhauser,
Independent Director -
Dr. Adebayo Laniyonu Ph.D.,
Sr. VP of Nonclinical Devel. -
Clint Tomlinson,
VP of Corp. -
Dr. Walter E. Kaufmann M.D.,
Chief Medical Officer -
Dr. Emmanuel O. Fadiran RPh, Ph.D.,
Sr. VP of Regulatory Affairs -
Stephan Toutain,
Chief Operating Officer -
Bernd Metzner,
Director -
Jiong Ma,
Director -
Cameron Durrant,
Director -
Harvey Lalach,
President, CFO -
Alison E. Ayers,
Director -
David L. Tousley,
Director -
George F Tidmarsh,
Executive Director -
Panos Kontzalis,
CEO -
George Kalkanis,
VP Strategic Planning -
Angela Vernadaki,
VP Business Development